|
Gene: SELE |
Gene summary for SELE |
Gene summary. |
Gene information | Species | Human | Gene symbol | SELE | Gene ID | 6401 |
Gene name | selectin E | |
Gene Alias | CD62E | |
Cytomap | 1q24.2 | |
Gene Type | protein-coding | GO ID | GO:0002090 | UniProtAcc | P16581 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6401 | SELE | P2T-E | Human | Esophagus | ESCC | 2.96e-09 | 9.01e-01 | 0.1177 |
6401 | SELE | P38T-E | Human | Esophagus | ESCC | 3.60e-04 | 2.01e-01 | 0.127 |
6401 | SELE | P61T-E | Human | Esophagus | ESCC | 1.63e-06 | 6.22e-02 | 0.099 |
6401 | SELE | P80T-E | Human | Esophagus | ESCC | 2.02e-02 | 5.43e-02 | 0.155 |
6401 | SELE | P127T-E | Human | Esophagus | ESCC | 7.96e-04 | 2.63e-02 | 0.0826 |
6401 | SELE | P128T-E | Human | Esophagus | ESCC | 5.36e-31 | 1.16e+00 | 0.1241 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00621979 | Breast | Precancer | cellular response to chemical stress | 51/1080 | 337/18723 | 2.40e-10 | 2.34e-08 | 51 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00069869 | Breast | Precancer | response to unfolded protein | 28/1080 | 137/18723 | 3.81e-09 | 3.00e-07 | 28 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00345999 | Breast | Precancer | cellular response to oxidative stress | 42/1080 | 288/18723 | 2.78e-08 | 1.79e-06 | 42 |
GO:00359669 | Breast | Precancer | response to topologically incorrect protein | 29/1080 | 159/18723 | 3.00e-08 | 1.89e-06 | 29 |
GO:00349769 | Breast | Precancer | response to endoplasmic reticulum stress | 38/1080 | 256/18723 | 7.89e-08 | 4.60e-06 | 38 |
GO:00346209 | Breast | Precancer | cellular response to unfolded protein | 21/1080 | 96/18723 | 9.80e-08 | 5.46e-06 | 21 |
GO:00104989 | Breast | Precancer | proteasomal protein catabolic process | 58/1080 | 490/18723 | 1.54e-07 | 8.05e-06 | 58 |
GO:00509006 | Breast | Precancer | leukocyte migration | 47/1080 | 369/18723 | 2.82e-07 | 1.39e-05 | 47 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00359679 | Breast | Precancer | cellular response to topologically incorrect protein | 22/1080 | 116/18723 | 6.84e-07 | 2.80e-05 | 22 |
GO:00988698 | Breast | Precancer | cellular oxidant detoxification | 20/1080 | 101/18723 | 1.07e-06 | 4.18e-05 | 20 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493317 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SELE | CD44 | SELE_CD44 | SELE | Breast | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Breast | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Breast | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Breast | Healthy |
SELE | GLG1 | SELE_GLG1 | SELE | Breast | Healthy |
SELPLG | SELE | SELPLG_SELE | SELPLG | Breast | Healthy |
SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Breast | Healthy |
SELE | CD44 | SELE_CD44 | SELE | Breast | Precancer |
SELE | CD44 | SELE_CD44 | SELE | Cervix | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Cervix | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Cervix | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Cervix | CC |
SELE | GLG1 | SELE_GLG1 | SELE | Cervix | CC |
SELE | CEACAM1 | SELE_CEACAM1 | CEACAM | Cervix | CC |
SELPLG | SELE | SELPLG_SELE | SELPLG | Cervix | CC |
SELE | CD44 | SELE_CD44 | SELE | Endometrium | ADJ |
SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | ADJ |
SELPLG | SELE | SELPLG_SELE | SELPLG | Endometrium | ADJ |
SELE | CD44 | SELE_CD44 | SELE | Endometrium | AEH |
SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | AEH |
Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SELE | SNV | Missense_Mutation | c.80N>G | p.Ser27Cys | p.S27C | P16581 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SELE | SNV | Missense_Mutation | novel | c.464N>G | p.Val155Gly | p.V155G | P16581 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SELE | insertion | In_Frame_Ins | novel | c.465_466insACT | p.Val155_Glu156insThr | p.V155_E156insT | P16581 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
SELE | SNV | Missense_Mutation | c.1681N>T | p.Leu561Phe | p.L561F | P16581 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
SELE | SNV | Missense_Mutation | c.113N>A | p.Ala38Asp | p.A38D | P16581 | protein_coding | tolerated(0.57) | benign(0.009) | TCGA-VS-A9UB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SELE | SNV | Missense_Mutation | novel | c.518A>G | p.Lys173Arg | p.K173R | P16581 | protein_coding | tolerated(0.53) | benign(0.003) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
SELE | SNV | Missense_Mutation | c.1408N>G | p.Ser470Ala | p.S470A | P16581 | protein_coding | tolerated(0.13) | benign(0.217) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
SELE | SNV | Missense_Mutation | c.113N>T | p.Ala38Val | p.A38V | P16581 | protein_coding | tolerated(0.25) | benign(0.069) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SELE | SNV | Missense_Mutation | novel | c.544G>A | p.Ala182Thr | p.A182T | P16581 | protein_coding | tolerated(0.24) | possibly_damaging(0.543) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SELE | SNV | Missense_Mutation | c.1758G>T | p.Lys586Asn | p.K586N | P16581 | protein_coding | deleterious(0) | benign(0.42) | TCGA-AZ-4614-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | leucovorin | LEUCOVORIN | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | BIMOSIAMOSE | BIMOSIAMOSE | ||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | fluorouracil | FLUOROURACIL | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | capecitabine | CAPECITABINE | 24980946 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1215923 | BIMOSIAMOSE | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | Bimosiamose | BIMOSIAMOSE | ||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GMI-1359 | |||
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | GMI-1070 | RIVIPANSEL | 20508165 | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL3707446 | RIVIPANSEL | |
6401 | SELE | DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | SIALYL LEWIS X | SIALYL LEWIS X |
Page: 1 2 |